Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.
Curia, a contract research development and manufacturing organization, will acquire Californian formulation and fill-finish organization Integrity Bio.
Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozyme’s technology, for the treatment of breast cancer, has received approval from Health Canada.